Article
A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
All News
Article
Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.
Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. We also have two call-in cases on "Ask Cush Anything".
Be sure to join in the fun at RNL 2025 next weekend - Gong Show Karaoke; what will you sing?
Dr. John Cush
Tweet
Obinutuzumab Efficacy in Active Lupus Nephritis
A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
https://t.co/e1cDvJcC9g https://t.co/HUDd1ocAvc
Dr. John Cush
Tweet
SLE subphenotypes predisposed by distinct genetic risk loci. Multicenter 10 yr genotyping study on 1462 SLE pts (56% w/ lupus nephritis & 43% not LN) found significantly higher polygenic risk scores (PRS); significant LN variants included HLA, TNFAIP3, BLK, & STAT4.… https://t.co/5igpgtdE1U https://t.co/5KOXRThzlk
Eric Dein
Tweet
P2 Trial: DEU in PsA
Encouraging results for DCV 6 and 12 mg qd.
ACR20 63% for DCV 12 mg (p=0.0004)
Not yet FDA approved for PsA, only PsO
Pending P3
P2: DEU in SLE - PAISLEY
Improved SRI(4), CLASI-50 at w32
Merola
#RNL2025 @RheumNow https://t.co/RV7OPaZWjx
Janet Pope
Tweet
Break a leg! Or a #hip
#AVN risk occurs even at 1 month of high / moderate dose #glucocorticoids
Shown by Michelle Petri @RheumNow #RNL2025
Risk in SLE is likely
👇
#disease #activity
And
#steroids
#SLE #systemic #lupus #erythematosus #steroids https://t.co/4EsQw9tY1u
Janet Pope
Tweet
Even a #SLE expert who wants all #lupus Pts on
No #chronic #prednisone
Realizes you can’t get everyone off #glucocorticoids
18% May be on chronic #steroids
But she keeps trying to taper
Michelle Petri
#RNL2025 @RheumNow https://t.co/SNP6Eep731
Adela Castro
Tweet
M. Petri on Steroids in SLE👇
-Organ damage is higher in AA vs Caucasians-driven by CS
-CV risk increase is dose dependent:
>10 mg =2x risk
>20mg =5x risk
-Increase prednisone by 10mg =30% increased risk for organ damage! 🤯
-20mg/day >1m increases risk for… https://t.co/fZVjS7JQBL
Dr. John Cush
Tweet
QD Clinic - dsDNA without Lupus
Insufficient Sxs to Dx SLE, but persistent dsDNA positivity - what to do?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/hCXRhTJB7G https://t.co/y3Tzh5bRLJ
Janet Pope
Tweet
Wise person once said
If you don’t take your medications,
THEY DON’T WORK!
Shocking 1 in 3 nonadherence with
#hydroxychloroquine
By drug levels
In young Pts with
#SLE #lupus
Michelle Petri @RheumNow #RNL2025 https://t.co/H5izbnW0qU
Dr. John Cush
Tweet
QD Clinic - dsDNA without Lupus
Insufficient Sxs to Dx SLE, but persistent dsDNA positivity - what to do?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/ov8THqrPyC https://t.co/jmtqxcWzJ0
Dr. John Cush
Tweet
SLE subphenotypes predisposed by distinct genetic risk loci. Multicenter 10 yr genotyping study on 1462 SLE pts (56% w/ lupus nephritis & 43% not LN) found significantly higher polygenic risk scores (PRS); significant LN variants included HLA, TNFAIP3, BLK, & STAT4.… https://t.co/zvYGct9aqG https://t.co/obgkHbXNWA
Dr. John Cush
Tweet
Congratulations to 2025 Crafoord Prize (in Polyarthritis) laureates Christopher Goodnow, (UNSW Sydney, Australia), and David Nemazee (Scripss,, USA) for their work on tolerance checkpoints - prevent B cells from attacking the body’s own tissues in autoimmune diseases… https://t.co/WSyXVIFJa1 https://t.co/JtBau2JSvo
Dr. John Cush
Tweet
UK NHS 2023-24 figures show hospitalization for SLE is 8X more common in blacks (62.6 per 100,000) compared to white SLE (7.8/100K) and Asian SLE (26/100K), Lupus hospitalizations risen 50% in 4 yrs (6,334 to 8,006 in 2023-24). Is this “stark” inequality from delayed Dx?… https://t.co/NDdIkWKZy5 https://t.co/E4Fmvz9uLn
Dr. John Cush
Tweet
Cross-sectional study of 50 SLE patients, 24% had fibromyalgianess, and 18% experienced widespread pain. Fibromyalgianess in SLE patients primarily reflects heightened pain sensitivity and symptom severity rather than SLE disease activity. https://t.co/oLYc4IsIpN https://t.co/eHVIe9OXVF
Dr. John Cush
Tweet
Korean Study of 10,013 #SLE pts (91%F)those on immunosuppressives were not at greater risk for cancer. Total CA risk (n 368) was 59 per 10,000 PYs. Most common Thyroid, breast, Gastric, colon & cervical. https://t.co/R0s7ZXaUoX https://t.co/jAc5mgtmlm
Dr. John Cush
Tweet
Cardiovascular Risk in Cutaneous Lupus Erythematosus
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
https://t.co/QimKD9klM2 https://t.co/2Yb0tWoOB0
Dr. John Cush
Tweet
QD Clinic - ANA Negative Lupus
Pregnant ANA negative SLE (?) patients with Sjogrens and FM - what to do?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/RyCdiadn4H https://t.co/EvWcQ6KIxQ
Dr. John Cush
Tweet
Cardiovascular Risk in Cutaneous Lupus Erythematosus
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
https://t.co/3gEkFBK8wc https://t.co/kagpp7w7nE
